CDER Advisory Panel Vacancies Remain High As Overall FDA Rates Improve
This article was originally published in The Pink Sheet Daily
Executive Summary
Empty slots on CDER advisory panels holding agency back from meeting goal vacancy rate as other centers fill more panel slots.
You may also be interested in...
FDA-Industry Relations Faulted As 'Revolving Door' In BMJ Report
Academic authors say that more than half of FDA medical reviewers leave to either work or consult to industry; experts chime in with mixed reactions to the findings.
CDER Advisory Committee Staffing Improves, But Trouble Spots Remain
After years of widespread vacancies on advisory committees, the Food & Drug Administration appears to have tackled most of the problems. But there are a couple of significant outliers, most significantly the Dermatology & Ophthalmic Products Advisory Committee. Will changes in conflict of interest rules and a new recruitment effort help FDA find and retain advisory committee members?
Conflict of Interest Reform: Greatest Impact May Be Committee Vacancy Rate
FDA user fee reauthorization eliminates limits on waivers, which may ease the burden on FDA to fill open seats on its advisory committees. Vacancy rates have been as high as 24% in FY 2012.